Drug development risk and the cost of capital

被引:12
作者
Baras, Aris I. [1 ,2 ,3 ]
Baras, Alex S. [4 ]
Schulman, Kevin A. [1 ,2 ]
机构
[1] Duke Univ, Sch Med, Durham, NC 27710 USA
[2] Duke Univ, Hlth Sect, Fuqua Sch Business, Management Program, Durham, NC 27708 USA
[3] Liquidia Technol, Morrisville, NC 27560 USA
[4] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
关键词
D O I
10.1038/nrd3722
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
This article analyses the relationship between risk and the cost of capital for projects in different stages of drug development and describes a framework that could improve portfolio optimization strategies.
引用
收藏
页码:347 / 348
页数:2
相关论文
共 4 条
[1]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[2]  
Myers S. C., 1997, MIT PROGRAM PHARM IN
[3]  
Myers S. C., 1996, COMPETITIVE STRATEGI, V10, P208
[4]  
Stewart J. J., 2009, NAT BIOTECHNOL, V27, P1